A snapshot of the precision medicine landscape
What needs to happen to facilitate data sharing, ensure access to genome sequencing and promising personalized therapies?
Cabaletta Bio closes $50M Series B round for cell-based autoimmune disease therapies
The latest fund raise brings the total funding the company has received since May to $88 million, which it will use to develop CAAR-T therapies, similar to CAR-Ts used in cancers.
Where Will AI Deployment Benefit Payers the Most?
We are taking a look at how health insurers are using AI, defining success, and managing cybersecurity risks. Give us your opinions by completing our brief, anonymous survey.